Phaseline

Companies › Generate Biomedicines

Generate Biomedicines: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 3; Respiratory, Immunology, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GB-0895–Phase 3Severe Asthma; AsthmaMay 2027
GB-7624–Phase 1Atopic Dermatitis (AD)Dec 2026
GB-4362
Monoclonal antibody that binds and neutralizes free monomethyl auristatin E (MMAE)
–Phase 1Advanced Urothelial CancerJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06920693GB-7624Phase 1Atopic Dermatitis (AD)ImmunologyDec 2026
NCT07116889GB-0895Phase 1AsthmaRespiratoryMay 2027
NCT07484022GB-4362Phase 1Advanced Urothelial CancerOncologyJun 2027
NCT07276724GB-0895Phase 3Severe AsthmaRespiratoryDec 2028
NCT07359846GB-0895Phase 3Severe AsthmaRespiratoryJan 2029

From the company's SEC filings

Cash and short-term investments of $457m on 2026-06-30; operating cash outflow about $281m a year; runway about 20 months at that burn, to Feb 2028; 0 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Fate Therapeutics Kura Oncology Suzhou Zelgen Biopharmaceuticals Eikon Therapeutics Arcus Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.